Effetti della somministrazione di buprenorfina transdermica in pazienti oncologici. Risultati di uno studio di outcome

Translated title of the contribution: Effects of transdermal buprenorphine in cancer patients. Results from the Cancer Pain Outcome Research (CPOR) Study Group

Maria Teresa Greco, Silvia Deandrea, Oscar Corli, Mauro Montanari, Augusto Caraceni, Giovanni Apolone

Research output: Contribution to journalArticle

Abstract

Pain still afflicts most cancer patients, mainly in the metastatic phases, and undertreatment is well documented. Transdermal delivery systems (TDS) could potentially have advantages over oral and parental routes, but evidence from comparative trials are scanty. In the framework of a wider initiative, an Outcome Research Study was carried out in Italy in 2006 to evaluate the effects of various analgesic options, particularly TDS Buprenorphine. Despite the limitations due to the observational design, these findings may be useful to clinicians to better judge the value of the drug under evaluation and to help researchers to design further comparative studies.

Translated title of the contributionEffects of transdermal buprenorphine in cancer patients. Results from the Cancer Pain Outcome Research (CPOR) Study Group
Original languageItalian
Pages (from-to)538-551
Number of pages14
JournalRecenti Progressi in Medicina
Volume99
Issue number11
Publication statusPublished - Nov 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Effects of transdermal buprenorphine in cancer patients. Results from the Cancer Pain Outcome Research (CPOR) Study Group'. Together they form a unique fingerprint.

  • Cite this